Audenz™ (Influenza A [H5N1] Monovalent Vaccine, Adjuvanted) – New drug approval
January 31, 2020 - The FDA approved Seqirus’ Audenz (Influenza A [H5N1] Monovalent Vaccine, Adjuvanted), for active immunization for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine. Audenz is approved for use in persons 6 months of age and older at increased risk of exposure to the influenza A H5N1 virus subtype contained in the vaccine.
Top